MedTrace Logo

OmegaChild - Omega-3 Supplementation to Children Previously Treated for Cancer

NCT02134600 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-08-28

No results posted yet for this study

Summary

The purpose of this study is to find an optimal dose of omega-3 that can be given to children who have completed cancer therapy. The future aim is to add omega-3 to conventional cancer treatment modalities and thereby hopefully increase the treatment efficacy, which will have to be addressed in subsequent phase-2 studies.

Conditions

  • Pediatric Cancer

Interventions

DIETARY_SUPPLEMENT

Omega-3 enriched fruit juice

Different doses of omega-3 will be administered to five different groups: 400, 800, 1200, 2400 and 3000 mg/m2.

Sponsors & Collaborators

  • Smartfish AS

    collaborator INDUSTRY

  • Per Kogner

    lead OTHER

Principal Investigators

  • Per Kogner, Professor · Karolinska Institutet

Study Design

Allocation
NA
Purpose
SUPPORTIVE_CARE
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2016-08-31
Completion
2016-09-02

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02134600 on ClinicalTrials.gov